PharmaCyte Biotech Inc (PMCB) — Working Capital to Net Assets Ratio
PharmaCyte Biotech Inc (PMCB) has a Working Capital to Net Assets ratio of 48.3% as of January 2026. Working capital of $19.02 Million (current assets of $20.70 Million minus current liabilities of $1.68 Million) is measured against net assets of $39.40 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See PMCB equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
PharmaCyte Biotech Inc Working Capital to Net Assets (2004–2025)
This chart shows how PharmaCyte Biotech Inc's Working Capital to Net Assets ratio has evolved across 22 annual periods from 2004 to 2025. As of January 2026, the ratio stands at 48.3%, reflecting working capital of $19.02 Million against net assets of $39.40 Million USD. Check PMCB goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for PharmaCyte Biotech Inc (2004–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for PharmaCyte Biotech Inc from 2004 to 2025, covering 22 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of PharmaCyte Biotech Inc.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 37.5% | $19.46 Million | $51.89 Million | $22.38 Million | $2.91 Million | ▼ -71.4 pp |
| 2024 | 108.9% | $43.02 Million | $39.51 Million | $50.44 Million | $7.42 Million | ▲ +15.9 pp |
| 2023 | 92.9% | $67.56 Million | $72.69 Million | $68.15 Million | $586.58K | ▼ -1.4 pp |
| 2022 | 94.3% | $84.79 Million | $89.92 Million | $85.49 Million | $704.37K | ▲ +71.1 pp |
| 2021 | 23.2% | $1.55 Million | $6.68 Million | $2.28 Million | $724.78K | ▲ +23.1 pp |
| 2020 | 0.1% | $6.25K | $5.09 Million | $1.04 Million | $1.03 Million | ▲ +1.9 pp |
| 2019 | -1.8% | $-89.45K | $5.04 Million | $653.40K | $742.85K | ▼ -12.9 pp |
| 2018 | 11.1% | $639.70K | $5.77 Million | $1.28 Million | $644.17K | ▼ -25.5 pp |
| 2017 | 36.6% | $2.96 Million | $8.09 Million | $3.54 Million | $580.25K | ▲ +15.2 pp |
| 2016 | 21.4% | $1.39 Million | $6.52 Million | $2.03 Million | $637.64K | ▲ +7.8 pp |
| 2015 | 13.6% | $806.58K | $5.94 Million | $2.82 Million | $2.01 Million | ▼ -29.1 pp |
| 2014 | 42.6% | $3.81 Million | $8.94 Million | $4.19 Million | $373.67K | ▼ -169.0 pp |
| 2013 | 211.6% | $-1.95 Million | $-921.46K | $1.85 Million | $3.80 Million | ▲ +92.0 pp |
| 2012 | 119.7% | $-2.73 Million | $-2.28 Million | $1.06 Million | $3.79 Million | ▼ -0.7 pp |
| 2011 | 120.4% | $-3.28 Million | $-2.73 Million | $104.75K | $3.39 Million | ▼ -35.4 pp |
| 2010 | 155.8% | $-3.04 Million | $-1.95 Million | $13.68K | $3.05 Million | ▲ +149.2 pp |
| 2009 | 6.6% | $263.94K | $3.99 Million | $1.18 Million | $918.80K | ▼ -41.2 pp |
| 2008 | 47.8% | $3.55 Million | $7.44 Million | $3.74 Million | $180.56K | ▼ -29.5 pp |
| 2007 | 77.3% | $3.31 Million | $4.29 Million | $3.43 Million | $118.81K | ▲ +8.8 pp |
| 2006 | 68.5% | $3.02 Million | $4.41 Million | $3.13 Million | $106.21K | ▲ +64.4 pp |
| 2005 | 4.1% | $-53.38K | $-1.30 Million | $244.06K | $297.45K | ▲ +89.1 pp |
| 2004 | -85.0% | $130.45K | $-153.43K | $130.71K | $260.00 | — |